Esperion Therapeutics, Inc. (ESPR)

Market Cap	671.71M
Revenue (ttm)	268.13M
Net Income (ttm)	-104.02M
Shares Out	231.62M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	13.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,170,732
Open	2.750
Previous Close	2.710
Day's Range	2.730 - 2.920
52-Week Range	0.693 - 3.940
Beta	0.96
Analysts	Buy
Price Target	6.50 (+124.14%)
Earnings Date	Nov 6, 2025

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 26, 2013
• Employees: 304
• Stock Exchange: NASDAQ
• Ticker Symbol: ESPR
• Website: https://www.esperion.com

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 124.14% from the latest price.

Price Target

$6.5

(124.14% upside)

Analyst Consensus: Buy